QUANTUM GENOMICS Provient regroupement Aktie
0,07EUR | -0,03EUR | -34,46% |
WKN DE: A1XAEB / ISIN: FR0011648971
Personal
2019 | 2020 | 2021 | 2022 | 2023 | |
---|---|---|---|---|---|
Personal am Ende des Jahres | 13 | 9 | 7 | 0 | 0 |
Umsatz pro Mitarbeiter in Mio. EUR | 0,00 | 0,20 | 0,45 | 0,00 | 0,00 |
Bilanz (in Mio. EUR) - Aktiva
2019 | 2020 | 2021 | 2022 | 2023 | |
---|---|---|---|---|---|
Summe Umlaufvermögen | 14 | 32 | 20 | 23 | 4 |
Summe Anlagevermögen | 1 | 1 | 1 | 0 | 0 |
Summe Aktiva | 15 | 33 | 21 | 24 | 4 |
Bilanz (in Mio. EUR) - Passiva
2019 | 2020 | 2021 | 2022 | 2023 | |
---|---|---|---|---|---|
Summe Fremdkapital | 5 | 8 | 12 | 20 | 3 |
Summe Eigenkapital | 10 | 25 | 10 | 4 | 0 |
Summe Passiva | 15 | 33 | 21 | 24 | 4 |
Adresse
33 Rue Marbeuf, 75008 Paris | |
Telefon | +33 (1) 85-34-77-70 |
Internet | http://www.quantum-genomics.com |
Management
Benoît Gueugnon
Chief Financial & Investor Relations Officer |
Bruno Besse
Chief Medical Officer |
Carole Wassermann
Director |
Fabrice Balavoine
Director-Research & Development |
François Durvye
Director |
François Pelen
Director |
Jean-Philippe Milon
Chairman & Chief Executive Officer |
Lionel Ségard
Director |
Sarah Merlen-Boulenger
Head-Regulatory Affairs |